Acute lung injury: epidemiology, pathogenesis, and treatment

J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):243-52. doi: 10.1089/jamp.2009.0775.


Acute lung injury (ALI) remains a significant source of morbidity and mortality in the critically ill patient population. Defined by a constellation of clinical criteria (acute onset of bilateral pulmonary infiltrates with hypoxemia without evidence of hydrostatic pulmonary edema), ALI has a high incidence (200,000 per year in the US) and overall mortality remains high. Pathogenesis of ALI is explained by injury to both the vascular endothelium and alveolar epithelium. Recent advances in the understanding of pathophysiology have identified several biologic markers that are associated with worse clinical outcomes. Phase III clinical trials by the NHLBI ARDS Network have resulted in improvement in survival and a reduction in the duration of mechanical ventilation with a lung-protective ventilation strategy and fluid conservative protocol. Potential areas of future treatments include nutritional strategies, statin therapy, and mesenchymal stem cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Acute Lung Injury / epidemiology
  • Acute Lung Injury / etiology
  • Acute Lung Injury / therapy*
  • Animals
  • Enteral Nutrition
  • Fluid Therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Mesenchymal Stem Cell Transplantation
  • Respiration, Artificial


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors